Analysis | Virologic Failure or Other Discontinuation | Virologic Failure | Discontinuations due to Virologic Failure | Other Discontinuation | Virologic Suppression | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
aHR (95% CI) | p | aHR (95% CI) | p | aHR (95% CI) | p | aHR (95% CI) | p | aHR (95% CI) | p | ||
0 | Original Model | 0.76 (0.56,1.03) | 0.08 | 0.50 (0.28,0.91) | 0.02 | 0.00 (0.00,0.00) | <.0001 | 0.93 (0.65,1.33) | 0.68 | 0.99 (0.82,1.21) | 0.96 |
1 | Subgroup by Province | ||||||||||
ON/QC Only | 0.73 (0.51,1.06) | 0.10 | 0.90 (0.44,1.86) | 0.78 | 0.00 (0.00,0.00) | <.0001 | 0.72 (0.47,1.11) | 0.14 | 0.99 (0.78,1.27) | 0.96 | |
BC Only | 0.69 (0.34,1.42) | 0.32 | 0.41 (0.09,1.78) | 0.23 | 0.00 (0.00,0.00) | <.0001 | 0.93 (0.43,2.04) | 0.86 | 0.78 (0.46,1.32) | 0.35 | |
2 | Subgroup by Baseline VL | ||||||||||
< 100,000 copies/mL | 0.66 (0.42,1.03) | 0.07 | 0.47 (0.18,1.19) | 0.11 | 0.00 (0.00,0.00) | <.0001 | 0.82 (0.49,1.36) | 0.44 | 0.97 (0.76,1.23) | 0.78 | |
≥ 100,000 copies/mL | 0.86 (0.56,1.33) | 0.49 | 0.54 (0.25,1.16) | 0.11 | 0.00 (0.00,0.00) | <.0001 | 1.16 (0.68,2.00) | 0.58 | 1.11 (0.81,1.53) | 0.51 | |
3 | 2010–2012 Only | 0.81 (0.56,1.18) | 0.27 | 0.55 (0.26,1.14) | 0.11 | 0.00 (0.00,0.00) | <.0001 | 0.96 (0.63,1.48) | 0.87 | 0.98 (0.76,1.26) | 0.87 |
4 | Simplification discontinuations included as competing risks | 0.75 (0.54,1.03) | 0.07 | 0.50 (0.28,0.91) | 0.02 | 0.00 (0.00,0.00) | <.0001 | 0.92 (0.63,1.34) | 0.65 | 0.99 (0.82,1.21) | 0.96 |
5 | SMC-FCS Imputation | 0.76 (0.56, 1.04) | 0.08 | 0.5 (0.28, 0.9) | 0.02 | 0.00 (0.00,0.00) | <.0001 | 0.91 (0.62, 1.34) | 0.64 | 0.98 (0.8, 1.2) | 0.84 |